Following the product specific Pre-Approval Inspection (PAI) by the United States Food and Drug Administration (USFDA) at the Indore plant from 27th June, 2022 to 1st July, 2022, the Company has now received the Establishment Inspection Report (EIR) indicating closure of the inspection.